How High Will Brown Forman Stock Go?
On the surface, Brown‑Forman (NYSE: BF.B) is having an unremarkable year.…
Sell
27
SPRO Quote, Financials, Valuation and Earnings
Last price:
$2.38
Seasonality move
:
17.06%
Day range:
$2.35 - $2.53
52-week range:
$0.51 - $3.22
Dividend yield:
0%
P/E ratio:
10.75x
P/S ratio:
4.56x
P/B ratio:
3.92x
Volume:
970.6K
Avg. volume:
1.4M
1-year change:
66.9%
Market cap:
$132.5M
Revenue:
$27.4M
EPS (TTM):
-$1.28
Analysts' Opinion
-
Consensus RatingSpero Therapeutics has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.00, Spero Therapeutics has an estimated upside of 110.97% from its current price of $2.37.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $2.37.
Fair Value
-
According to the consensus of 2 analysts, Spero Therapeutics has 110.97% upside to fair value with a price target of $5.00 per share.
SPRO vs. S&P 500
-
Over the past 5 trading days, Spero Therapeutics has underperformed the S&P 500 by -16.16% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Spero Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Spero Therapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Spero Therapeutics reported revenues of $5.1M.
Earnings Growth
-
Spero Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Spero Therapeutics reported earnings per share of -$0.25.
Enterprise value:
83.6M
EV / Invested capital:
--
Price / LTM sales:
4.56x
EV / EBIT:
0.54x
EV / Revenue:
2.95x
PEG ratio (5yr expected):
0.02x
EV / Free cash flow:
-2.50x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
0.54x
Gross Profit (TTM):
--
Return On Assets:
-54.42%
Net Income Margin (TTM):
-246.49%
Return On Equity:
-108.26%
Return On Invested Capital:
-108.26%
Operating Margin:
-284.8%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $49.1M | $100.2M | $28.3M | $4.2M | $5.1M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$14.6M | $27M | -$73.1M | -$14M | -$14.6M | |
| EBITDA | -$26.9M | $27.3M | -$73.1M | -$14M | -$14.6M | |
| Diluted EPS | -$0.90 | $0.44 | -$1.28 | -$0.24 | -$0.25 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $129.5M | $132.7M | $101.7M | $140.2M | $74.7M | |
| Total Assets | $143.4M | $145.8M | $112.5M | $167.7M | $77.7M | |
| Current Liabilities | $17.8M | $69.2M | $23M | $41.8M | $29.2M | |
| Total Liabilities | $24.6M | $83.4M | $47.7M | $71.5M | $43.9M | |
| Total Equity | $118.8M | $62.5M | $64.8M | $96.2M | $33.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $7.6M | -$14.2M | -$33.4M | $5.9M | -$4M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | $7.6M | -$14.2M | -$33.4M | $5.9M | -$4M | |
SPRO
Sector
Market Cap
$132.5M
$34.9M
Price % of 52-Week High
73.6%
48.57%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
66.9%
-35.06%
Beta (5-Year)
1.331
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.64
200-day SMA
Buy
Level
$1.27
Bollinger Bands (100)
Buy
Level
0.46 - 2.44
Chaikin Money Flow
Sell
Level
-5.4M
20-day SMA
Sell
Level
$2.81
Relative Strength Index (RSI14)
Sell
Level
38.68
ADX Line
Sell
Level
20.17
Williams %R
Buy
Level
-97.7011
50-day SMA
Buy
Level
$2.16
MACD (12, 26)
Buy
Level
0.70
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Sell
Level
-3.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.5817)
Sell
CA Score
(Annual)
Level (-2.5206)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.7033)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Stock Forecast FAQ
In the current month, SPRO has received 0 Buy ratings 2 Hold ratings, and 0 Sell ratings. The SPRO average analyst price target in the past 3 months is $5.00.
-
Where Will Spero Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Spero Therapeutics share price will rise to $5.00 per share over the next 12 months.
-
What Do Analysts Say About Spero Therapeutics?
Analysts are divided on their view about Spero Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Spero Therapeutics is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Spero Therapeutics's Price Target?
The price target for Spero Therapeutics over the next 1-year time period is forecast to be $5.00 according to 2 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is SPRO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Spero Therapeutics is a Hold. 2 of 2 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of SPRO?
You can purchase shares of Spero Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Spero Therapeutics shares.
-
What Is The Spero Therapeutics Share Price Today?
Spero Therapeutics was last trading at $2.38 per share. This represents the most recent stock quote for Spero Therapeutics. Yesterday, Spero Therapeutics closed at $2.37 per share.
-
How To Buy Spero Therapeutics Stock Online?
In order to purchase Spero Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Bloom Energy Flying Under the Radar?
Bloom Energy (NYSE:BE) manufactures scalable fuel cells for providing on-site…
Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
61
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
55
TLN alert for Jul 19
Talen Energy [TLN] is up 24.44% over the past day.
Sell
48
CRSP alert for Jul 19
CRISPR Therapeutics AG [CRSP] is up 18.22% over the past day.
Buy
83
SOC alert for Jul 19
Sable Offshore [SOC] is up 11.86% over the past day.
